These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
552 related articles for article (PubMed ID: 23616245)
1. Low-dose cytarabine and aclarubicin combined with granulocyte colony-stimulating factor for the treatment of relapsed or primary refractory acute lymphocytic leukemia: a retrospective study of 25 Chinese patients. Xue SL; Cui HX; Zou JY; Xue MX; Tang XW; Zhang YM; Wu DP Hematol Oncol; 2013 Dec; 31(4):206-12. PubMed ID: 23616245 [TBL] [Abstract][Full Text] [Related]
2. Increasing aclarubicin dose in low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) is efficacious as salvage chemotherapy for relapsed/refractory mixed-phenotype acute leukemia. Liu L; Qu Q; Jiao W; Zhang Y; Li X; Ding C; Wu D Leuk Res; 2015 Aug; 39(8):805-11. PubMed ID: 26021434 [TBL] [Abstract][Full Text] [Related]
3. Efficacy of low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) compared to Hyper-CVAD regimen as salvage chemotherapy in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia. Liu L; Jiao W; Zhang Y; Qu Q; Li X; Wu D Leuk Res; 2015 Mar; 39(3):323-8. PubMed ID: 25638269 [TBL] [Abstract][Full Text] [Related]
4. CAG regimen enables relapsed or refractory T-cell acute lymphocytic leukemia patients to achieve complete remission: a report of six cases. Xue SL; Wu DP; Sun AN; Tang XW Am J Hematol; 2008 Feb; 83(2):167-70. PubMed ID: 17874449 [TBL] [Abstract][Full Text] [Related]
5. Increasing aclarubicin dosage of the conventional CAG (low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor) regimen is more efficacious as a salvage therapy than CAG for relapsed/refractory acute myeloid leukemia. Qu Q; Liu L; Zhang Y; Li X; Wu D Leuk Res; 2015 Dec; 39(12):1353-9. PubMed ID: 26432074 [TBL] [Abstract][Full Text] [Related]
6. FLAG-IDA in the treatment of refractory/relapsed adult acute lymphoblastic leukemia. Specchia G; Pastore D; Carluccio P; Liso A; Mestice A; Rizzi R; Ciuffreda L; Pietrantuono G; Liso V Ann Hematol; 2005 Nov; 84(12):792-5. PubMed ID: 16047203 [TBL] [Abstract][Full Text] [Related]
7. Salvage chemotherapy with low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor priming in patients with refractory or relapsed acute myeloid leukemia with translocation (8;21). Wang Y; Li W; Chen S; Qiu H; Sun A; Wu D Leuk Res; 2011 May; 35(5):604-7. PubMed ID: 21130493 [TBL] [Abstract][Full Text] [Related]
8. Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AML) and previously untreated elderly patients with AML, secondary AML, and refractory anemia with excess blasts in transformation. Saito K; Nakamura Y; Aoyagi M; Waga K; Yamamoto K; Aoyagi A; Inoue F; Nakamura Y; Arai Y; Tadokoro J; Handa T; Tsurumi S; Arai H; Kawagoe Y; Gunnji H; Kitsukawa Y; Takahashi W; Furusawa S Int J Hematol; 2000 Apr; 71(3):238-44. PubMed ID: 10846828 [TBL] [Abstract][Full Text] [Related]
9. Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia. De Astis E; Clavio M; Raiola AM; Ghiso A; Guolo F; Minetto P; Galaverna F; Miglino M; Di Grazia C; Ballerini F; Marani C; Pastori G; Mitscheunig L; Cruciani F; Lovera D; Varaldo R; Ghiggi C; Lemoli RM; Bacigalupo A; Gobbi M Ann Hematol; 2014 Dec; 93(12):2011-8. PubMed ID: 24989345 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of G-CSF, low-dose cytarabine and aclarubicin in combination with l-asparaginase, prednisone in the treatment of refractory or relapsed acute lymphoblastic leukemia. Zhou K; Song Y; Zhang Y; Wei X; Fu Y; Yu F; Zhou H; Liu X; Zhou J; Fang B Leuk Res; 2017 Nov; 62():29-33. PubMed ID: 28982056 [TBL] [Abstract][Full Text] [Related]
11. DexaBEAM versus ICE salvage regimen prior to autologous transplantation for relapsed or refractory aggressive peripheral T cell lymphoma: a retrospective evaluation of parallel patient cohorts of one center. Mikesch JH; Kuhlmann M; Demant A; Krug U; Thoennissen GB; Schmidt E; Kessler T; Schliemann C; Pohlen M; Mohr M; Evers G; Köhler G; Wessling J; Mesters R; Müller-Tidow C; Berdel WE; Thoennissen NH Ann Hematol; 2013 Aug; 92(8):1041-8. PubMed ID: 23532626 [TBL] [Abstract][Full Text] [Related]
12. [Effect of modified FLAG regimen therapy on 33 patients with relapsed/refractory leukemia]. Meng FY; Yang LJ; Xu B; Liu XL; Zheng WY; Zhang Y; Huang F; Sun J; Liu QF Ai Zheng; 2003 Dec; 22(12):1330-3. PubMed ID: 14693062 [TBL] [Abstract][Full Text] [Related]
13. [Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor priming in 50 patients with relapsed acute myeloid leukemia]. Zhu BG; Qian SX; Hong M; Lu H; Wu HX; Zhang SJ; Qiu HX; Xu W; Li JY Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Jun; 17(3):760-4. PubMed ID: 19549403 [TBL] [Abstract][Full Text] [Related]
14. Cladribine with Granulocyte Colony-Stimulating Factor, Cytarabine, and Aclarubicin Regimen in Refractory/Relapsed Acute Myeloid Leukemia: A Phase II Multicenter Study. Wang H; Wang L; Li C; Wuxiao Z; Shao R; Wang H; Lu Y Oncologist; 2020 Nov; 25(11):e1663-e1670. PubMed ID: 32845551 [TBL] [Abstract][Full Text] [Related]
15. A single, high dose of idarubicin combined with cytarabine as induction therapy for adult patients with recurrent or refractory acute lymphoblastic leukemia. Weiss MA; Aliff TB; Tallman MS; Frankel SR; Kalaycio ME; Maslak PG; Jurcic JG; Scheinberg DA; Roma TE Cancer; 2002 Aug; 95(3):581-7. PubMed ID: 12209751 [TBL] [Abstract][Full Text] [Related]
16. Etoposide in combination with low-dose CAG (cytarabine, aclarubicin, G-CSF) for the treatment of relapsed or refractory acute myeloid leukemia: a multicenter, randomized control trial in southwest China. Zhang X; Li Y; Zhang Y; Chen X; Zhang C; Gao L; Kong P; Liu Y; Wen Q; Zeng Y; Wang Q; Su Y; Wang C; Wang S; Yuan Z; Gao L Leuk Res; 2013 Jun; 37(6):657-64. PubMed ID: 23537708 [TBL] [Abstract][Full Text] [Related]
17. Concurrent use of granulocyte colony-stimulating factor with low-dose cytosine arabinoside and aclarubicin for previously treated acute myelogenous leukemia: a pilot study. Yamada K; Furusawa S; Saito K; Waga K; Koike T; Arimura H; Aoyagi A; Yamato H; Sakuma H; Tsunogake S Leukemia; 1995 Jan; 9(1):10-4. PubMed ID: 7531259 [TBL] [Abstract][Full Text] [Related]
18. Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol. Martino R; Guardia R; Altés A; Sureda A; Brunet S; Sierra J Haematologica; 1999 Mar; 84(3):226-30. PubMed ID: 10189387 [TBL] [Abstract][Full Text] [Related]
19. Intensive salvage chemotherapy for primary refractory or first relapsed adult acute lymphoblastic leukemia: results of a prospective trial. Martino R; Bellido M; Brunet S; Altés A; Sureda A; Guárdia R; Aventín A; Nomdedéu JF; Domingo-Albós A; Sierra J Haematologica; 1999 Jun; 84(6):505-10. PubMed ID: 10366793 [TBL] [Abstract][Full Text] [Related]